Skip to main content

Table 3 BNP/NT-proBNP (pg/ml) levels at baseline and end of follow-up in the BNP-guided therapy group and symptom-guided therapy group

From: B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data

BNP/NT-proBNP (pg/ml)*
Studies that provided IPD Studies that provided aggregate data  
  Anguita [20] Northstar [27] Shochat [32] Starbrite [31] Upstep [34] Christchurch Pilot [29] Time-CHF [26, 33] Berger [21] Prima [22] Signal-HF [25] Battlescarred [28] Stars-BNP [23] Protect [30] Guide-It [11]
  n = 60 n = 407 n = 120 n = 130 n = 268 n = 69 n = 499 n = 278 n = 345 n = 252 n = 364 n = 220 n = 151  
BNP guided-therapy:
Baseline* 34 (7, 83) 1884 (1385, 2955) 1905 (1099, 4488) 453 (221, 1135) 601 (346, 946) 1839 HFrEF
3998
(2075, 7220)
HFpEF
2210
(1514–4081)
2216 (355, 9649) 2961
(discharge)
(1383, 5144)
2661 (2.1) 2012 (516, 10,233) 352 (260) 2344 2568
End of follow-up 8 (3, 83) 1765 (476, 3966) 413 (111, 894) 1169 2529 2360 1610 (6 months) 284
(180)
(3 months)
1125 1209
Difference 2 (−31, 28) −81 (− 1273, 512) −14 (− 461, 248) − 670 − 432 (− 1392, 297) −301 −402 − 68 1219 1359
% change from baseline: 6% −4% −3% −36% −15% − 11% − 20% − 19% −52% − 53%
Symptom-guided therapy:
Baseline* 22 (5, 104) 2042 (1390, 3560) 1569 (784, 4919) 441 (189, 981) 609 (376, 952) 2127 HFrEF
4657
(2455, 7520)
HFpEF
2191
(1478, 4890)
2469
(355, 18,487)
2936 (discharge)
(1291, 5525)
2429 (2.1) 1996 (425, 6588) 1946 2678
End of follow-up 39
(6, 104)
1822
(618, 4489)
471
(236, 1180)
2102 2364 2067 1537
(6 months)
1844 1397
Difference 4 (−20, 46) 73 (− 554, 1245) 51 (− 130, 288) −25 − 572 (− 1329, 434) − 362 − 459 102 1281
% change from baseline: 18% 5% 12% −1% −19.5% − 15% −23% −5% − 48%
  1. *Median (IQR) reported for all studies except Christchurch Pilot (type of summary statistic not reported), Protect (median only reported), Signal-HF (geometric mean reported), and Stars-BNP (mean reported)
  2. For all studies, BNP values at discharge from randomisation visit were used (assumed values at discharge reported if not stated otherwise in trial reports)
  3. For Northstar and Upstep, BNP values at the end of follow-up were not available. For the remaining studies providing IPD, the difference between the baseline and end of follow-up was calculated as the median (IQR) change from baseline across patients. For studies providing aggregate data, the change from baseline was calculated by taking the average BNP at end of follow-up from the average BNP at baseline.
  4. For all studies, the % change from baseline is calculated as the average difference as a percentage of the average baseline BNP